The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Pesonalised Risk Prediction For Severe Treatment-related Gastrointestinal Toxicity In Paediatric Cancer Patients Using Pre-treatment Gut Microbiome Analysis
Funder
National Health and Medical Research Council
Funding Amount
$408,768.00
Summary
The gut is home to trillions of good and bad bacteria, critical to human health. Each person has a different balance of bacteria, unique to their gut, which shapes their immune system and susceptibility to disease. I will investigate how the unique gut bacteria, in children with blood cancer, can be used to predict which children will develop severe gut side effects (diarrhoea) from their chemotherapy. This will identify high-risk children, enable personalised treatment and improve survival.
Assessment And Prediction Of Blood Flow Dynamics In Congenital Aortic Abnormalities Using Image-based Computer Modelling And Wave Intensity Analysis
Funder
National Health and Medical Research Council
Funding Amount
$390,925.00
Summary
Severe aortic abnormality is a serious problem in many infants with congenital heart disease, but it is often unclear what type of treatment will optimise blood flow and minimise the risk of later complications. This study aims to harness recent developments in blood flow modelling, magnetic resonance imaging and advanced blood flow analysis techniques to determine the factors that lead to complications in these children, thereby providing crucial information for improving treatment strategies.
Development Of Prognostic And Predictive Biomarkers To Aid Treatment Of Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$188,226.00
Summary
Although a number of new therapies are emerging in the treatment of lung cancer, chemotherapy remains the backbone of treatment for most patients. Currently we are unable to predict who will benefit from chemotherapy with some patients deriving no benefit but experiencing significant toxicity. Our group has investigated a number of biomarkers and found them to predict response to chemotherapy. These markers may be used to determine patients most likely to derive benefit from chemotherapy.
Kallikrein Gene Variants In Prostate Cancer: In-depth Association And Functional Studies
Funder
National Health and Medical Research Council
Funding Amount
$302,123.00
Summary
The number of men diagnosed with prostate cancer varies substantially between races, indicating a role of genetics in prostate cancer development. Recently, genetic variations in the PSA gene have been related to prostate cancer risk. I aim to elucidate the molecular mechanism of this correlation and to systematically investigate the association of other novel genetic variations in PSA and related genes with prostate cancer risk in a search of sensitive clinical biomarkers for prostate cancer di ....The number of men diagnosed with prostate cancer varies substantially between races, indicating a role of genetics in prostate cancer development. Recently, genetic variations in the PSA gene have been related to prostate cancer risk. I aim to elucidate the molecular mechanism of this correlation and to systematically investigate the association of other novel genetic variations in PSA and related genes with prostate cancer risk in a search of sensitive clinical biomarkers for prostate cancer diagnosis and prognosis.Read moreRead less